InterCure Ltd.
NASDAQ:INCRDrug Manufacturers - Specialty & Generic
-$0.04 today
- Market cap
- $51.63M
- Beta
- 0.57
- P/E (TTM)
- -4.3
- EPS (TTM)
- -$0.64
Volume 0.01M
Average 0.04M
INCR Capital Expenditures
Cash spent on property, plant, equipment, and other long-term assets.
InterCure Ltd.NASDAQ: INCR
Capital Expenditures · Q2 FY2025 · quarter ended Jun 2025
Capital expenditures grows in line with its trailing trend
Q2 FY2025 capital expenditures of ₪1.62M (cash outflow) rose 811.5% year over year, in line with the +811.5% change in trailing-twelve-month capital expenditures. Sequentially, it rose 0.0% from the prior quarter. Over 3 fiscal years it compounded at -43.6% a year.
Context
- Capital expenditures amounted to 1.3% of revenue in FY2025, down 0.5 pp from a year earlier.
- Capital expenditures grew in size in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +811.5% holds above the trailing-twelve-month pace of +811.5%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Capital Expenditures history
ILS · from the cash flow
- Latest · FY2025
- (3.55M) ILS
- Year-over-year change
- +18.9%
| Period | Period end | Capital Expenditures | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (3.55M) | +18.9% |
| FY2024 | 2024-12-31 | (4.38M) | -67.1% |
| FY2023 | 2023-12-31 | (2.62M) | +86.7% |
| FY2022 | 2022-12-31 | (19.74M) | -40.7% |
| FY2021 | 2021-12-31 | (14.03M) | — |
Capital Expenditures vs competitors
How INCR compares with its peers on the latest reported figures
- Peers report in different currencies, so capital expenditures is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +811.5% is the highest of 7, against a peer median of +23.8%.
- Capital expenditures amounts to 1.3% of revenue for INCR, versus a peer median of 0.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2025 | ₪3.25M ILS | +811.5% | -43.6% | 1.3% | |
HYFTMindWalk Holdings Corp. | LTM Jan 2026 | CA$745.58K CAD | -52.4% | -14.0% | 4.1% |
| LTM Mar 2026 | CA$60.26K CAD | +102.4% | -31.1% | — | |
| LTM Mar 2026 | $17K USD | -99.9% | -87.4% | 0.0% | |
| LTM Mar 2026 | $16K USD | -80.5% | +128.9% | — | |
| LTM Mar 2026 | $0 USD | +100.0% | — | 0.0% | |
| LTM Mar 2026 | $0 USD | — | — | 0.0% | |
| LTM Mar 2026 | $0 USD | +100.0% | — | — | |
| LTM Mar 2026 | $0 USD | — | — | 0.0% | |
| Peer median (excluding INCR) | — | +23.8% | -22.5% | 0.0% | |
Competitors are the stored peer set for INCR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 7.3M | 43.75M | (63.53M) | (72.79M) | (36.78M) |
| Depreciation & Amortization | 7.39M | 11.7M | 13.17M | 15.37M | 17.15M |
| Deferred Income Tax | 11.44M | 93K | 2.25M | (14.53M) | (7.32M) |
| Stock-Based Compensation | 6.45M | 8.91M | 2.59M | 2.28M | 2.43M |
| Change in Working Capital | (1.65M) | (3.02M) | (43.55M) | (9.19M) | 18.88M |
| Accounts Receivables | 8.39M | (18.29M) | (23.49M) | 13.26M | 9.29M |
| Inventory | (17.89M) | (75.99M) | 40.21M | (17.44M) | 15.95M |
| Accounts Payables | 2.79M | 57.03M | (47.63M) | (8.9M) | (8.82M) |
| Other Working Capital | 5.06M | 34.22M | (12.63M) | 3.88M | 2.46M |
| Other Non-Cash Items | (5.91M) | (10.16M) | 35.44M | 11.94M | 22.49M |
| Operating Cash Flow | 25.02M | 51.27M | (53.63M) | (66.93M) | 16.84M |
| Capital Expenditures | (14.03M) | (19.74M) | (2.62M) | (4.38M) | (3.55M) |
| Acquisitions (Net) | (19.09M) | (8.32M) | (4.2M) | 405K | 1.67M |
| Purchases of Investments | (1.25M) | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | (30.84M) | (114.44M) | 11.59M | 21.66M | (107K) |
| Investing Cash Flow | (65.21M) | (142.5M) | 4.77M | 17.69M | (1.99M) |
| Debt Repayment | 65.83M | 137.73M | (61.98M) | 7.74M | (29.13M) |
| Common Stock Issued | 128.73M | 0 | 0 | 34M | 1.5M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 3.38M | (17.28M) | (20.91M) | (15.29M) | (19.03M) |
| Financing Cash Flow | 197.94M | 120.45M | (82.89M) | 26.46M | (46.66M) |
| Effect of Forex Changes | (4.54M) | 7.16M | 297K | (39K) | (44K) |
| Net Change in Cash | 158.33M | 36.37M | (131.45M) | (22.82M) | (31.85M) |
| Free Cash Flow | 10.99M | 31.53M | (56.25M) | (71.3M) | 13.29M |
InterCure Ltd.
NASDAQ:INCR
Intrinsic Alpha fair value
Locked
Current Price
$3.98
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.